Clinical Trials Logo
  1. Home
  2. Leishmaniasis, Cutaneous
  3. NCT00508963
  4. Details
NCT00508963 Clinical Trial

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Leishmaniasis, Cutaneous Clinical Trial

Official title:
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT00508963
Other study ID # UCSF Infectious Diseases
Secondary ID
Status No longer available
Phase
First received
Last updated

Study information
Verified date May 2023
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Recruitment information / eligibility
Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biopsy proven new world cutaneous or mucocutaneous leishmania Exclusion Criteria: - Prolonged QT - Liver disease - Pancreatitis

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• sodium stibogluconate (Pentostam)
20 mg/kg IV every day for 20 or 28 days

Locations
Country Name City State
United States University of CA at San Francisco Hospitals and Clinics San Francisco California

Sponsors (1)
Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Terminated NCT01140191 - Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis Phase 2
Completed NCT03999970 - A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol N/A
Completed NCT00111553 - Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis Phase 1
Recruiting NCT03762070 - Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
Completed NCT02894008 - A Study of a New Leishmania Vaccine Candidate ChAd63-KH Phase 2
Completed NCT03303898 - ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - N/A
Recruiting NCT05094908 - Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis Phase 1
Completed NCT01083576 - Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Phase 2
Completed NCT03445897 - Miltefosine Plus IL Pentamidine for Bolivian CL Phase 2
Withdrawn NCT04072874 - Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis. Phase 1/Phase 2
Completed NCT01032382 - Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Phase 2
Completed NCT00480883 - Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol N/A
Recruiting NCT05708625 - Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis Phase 3
Completed NCT04841239 - Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis N/A
Completed NCT00469495 - Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis N/A
Completed NCT03294161 - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Phase 2
Completed NCT04888130 - Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
Completed NCT03969134 - A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL Phase 2
Completed NCT03096457 - Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Phase 2/Phase 3
No longer available NCT01641796 - Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis